Molecular Devices Introduces ScanLater Western Blot Detection System
Molecular Devices has launched the ScanLater Western Blot Detection System. The first of its kind system combines western blot membrane detection with a multimode microplate reader platform, eliminating the need to acquire a separate dedicated western blot system, saving both lab space and budget. The system is compatible with Molecular Devices’ SpectraMax i3 and SpectraMax Paradigm Platforms.
ScanLater System is a time-resolved fluorescence (TRF)-based western blot detection assay, an optimal detection method that reduces stray excitation light, resulting in lower background noise and higher sensitivity. The ScanLater System comprises the ScanLater Western Blot Detection Cartridge, ScanLater Western Blot Kit and image acquisition software powered by SoftMax Pro Software. ScanLater Western Blot Kits contain europium-labeled secondary antibodies designed to work with existing primary antibodies without further optimisation. This substrate-free method of western blot detection not only outperforms traditional chemiluminescence and fluorescence-based western blot detection, it also allows membrane detection at any time.
Users can add western blot detection capability to the SpectraMax i3 or SpectraMax Paradigm Platform in just minutes by installing the ScanLater Western Blot Detection Cartridge. The cartridge is driven by SoftMax Pro Software, enabling users to run both microplate-based assays and western blot membrane detection from one software platform. SoftMax Pro Software provides a simple interface for acquiring .tif based images which may be printed, saved or exported to third party analysis packages. Using an add-on for ImageJ in SoftMax Pro Software, ScanLater System images are seamlessly exported with a single click.
Kevin Chance, President at Molecular Devices, commented: “Molecular Devices is committed to developing novel applications for our microplate customers, offering them the widest range of utility possible. The addition of the ScanLater Western Blot Detection System follows the introduction of the MiniMax Imaging Cytometer earlier this year, with the SpectraMax i3 System now leading the market in terms of application breadth.”
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance